Fig. 1

Proportion of patients with baseline joint pair involvement (PJPS > 0) in ORAL Start. Patients were receiving A tofacitinib 5 mg BID, B tofacitinib 10 mg BID, and C methotrexate; assessment of baseline joint pair involvement (PJPS > 0) included each of the component joint pairs making up the 68/66-joint count. The hip was excluded, as swelling was not assessed. The total number of patients assessed at baseline was N = 956 (tofacitinib 5 mg BID: N = 373; tofacitinib 10 mg BID: N = 397; methotrexate: N = 186). Refer to Table 1 for the number and proportion of patients with specific joint involvement at baseline. AC, acromioclavicular; BID, twice daily; DIP, distal interphalangeal; IP, interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal; N, number of patients assessed at baseline; PIP, proximal interphalangeal; PJPS, paired joint pathology score; SC, sternoclavicular; TM, temporomandibular